Surovatamig

DB19420InvestigationalProtein Based Therapies

TNB-486 is under investigation in clinical trial NCT06564038 (A Study of AZD0486 Monotherapy or in Combination With Other Anti-cancer Agents for Mature B-cell Malignancies).

Mechanism: Pharmacologically active on B-lymphocyte antigen CD19 and T-cell surface glycoprotein CD3
Curator reviewed
Also known as: H-gamma4 heavy chain anti-CD3D/CD3E dimer, Homo sapiens (1-450) [VH (Homo sapiens IGHV3-9*01 (100%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123)-Homo sapiens IGHG4*01 nG4m(a) CH2 L92, G4v5 h P10, G4v4 CH2 A1.3, A1.2, G4v32 CH · immunoglobulin (H-gamma4_L-kappa)_VH-G4(h-CH2-CH3), anti-[Homo sapiens CD3D (CD3 delta) and CD3E (CD3 epsilon, Leu-4) dimer] and anti-[Homo sapiens CD19 (B lymphocyte surface antigen B4, Leu-12)], Homo sapiens and humanized monoclonal antibody asymetric, · Immunoglobulin G4 [231-proline,237-alanine,238-alanine,369-tryptophan], bispecific, anti-(human CD3 antigen) (human monoclonal AZD0486 ?4-chain) disulfide with human monoclonal AZD0486 ?-chain, (229?124?),(232?127?)-bis(disulfide) with immunoglobulin [12
Code names: AZD-0486 · TNB-486

Resolves to

Compound

UNII3QW12I37H1

Targets

P15391CD19

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Surovatamig, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account